One-stop CAR-NKT Therapy Development

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The remarkable results of chimeric antigen receptors (CARs) clinical studies have improved the function and therapeutic efficacy of redirected T cells. However, several challenges have been encountered, and limit their anti-tumor potential and increase the risk of toxicity due to the high heterogeneity of CAR-T cells. Natural killer T cells (NKT) are immune cells, known for their powerful anti-cancer properties, and show potential for enabling autologous and allogeneic/off-the-shelf cancer immunotherapy.

At Creative Biolabs, we provide one-stop services for CAR-NKT therapy development, ranging from CAR construct design and optimization, CAR virus particle packaging, CAR carrying NKT cell engineering, to preclinical and clinical evaluation of CAR cells. We are dedicated to providing high-quality customized service to best meet your research needs, turnaround time, and budget requirements.

Advantages of CAR-NKT cells over conventional CAR-T cells

NKT cells have a spectrum of anti-tumor activities.
NKT cells would be able to directly kill tumor cells.
NKT cell activation indirectly activates two other types of immune cells, NK and T cells, to promotes an anti-tumor response.
Most importantly, in contrast to CAR-T cells from the same donors, CAR NKTs did not induce multi-organ graft-versus-host disease.

The potential of iPSC-derived NK cells as a template for engineering. Fig.1 Functional advantages of CAR-NKT cells over conventional CAR-T cells. (Shissler, 2017)

iPS-NKT Cells Platform for CAR-NKT Therapy Development

Creative Biolabs has developed a state-of-art CAR-Stem Cell Platform for manufacturing iPSC-NKT cells. The workflow mainly consists of the following steps:

1) NKT reprogramming

NKT cells extracted from a healthy donor are reprogrammed to generate NKT-iPSC (NKT cell-derived iPSC), which exhibits unlimited expansion capacity.

2) NKT-iPSC differention

The NKT-iPSC is stimulated by cytokines to differentiate into iPSC-NKT (iPSC NKT-derived regenerated NKT) cells, resulting in a population of iPSC-derived CAR-NKT cells that can be used for multiple patients.

3) Tumor recognition and killing

The iPSC-derived CAR-NKT cells infused in the patient selectively recognize the tumor cells expressing the antigen and mediate the killing.

Fig 2. Workflow for our iPSC-derived NKT cell platform.

One-Stop CAR-NKT Therapy Development

As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs provides one-stop services for CAR-NKT therapy development, including but not limited to:

If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.

Reference

Shissler, S. C., et al. (2017). Mixed signals: co-stimulation in invariant natural killer T cell-mediated cancer immunotherapy. Frontiers in immunology, 8, 1447.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION